Ajinomoto Co., Ltd.

Ea Pharma Co., Ltd.

Wataru Miyanaga

Masaru Takayanagi

Takao Ikenoue

Satoru Okamoto

Hideyuki Tanaka

Naoyuki Fukuchi

Naoyuki Yamada

Ryusuke Hirama

Sen Takeshita

Yumiko Fukuda

Naoko Arashida

Toshihiro Hatanaka

Seiji Niwa

Nobuo Kondo

Yoko Masuzawa

Akiyo Yamazaki

Munetaka Tokumasu

Yoko Kageyama

Itsuya Tanabe

Misato Noguchi

Ayatoshi Ando

Yuki Saitou

Tatsuya Ishikawa

Atsushi Tsuruta

Nobuhiko Hayakawa

Masatsugu Noguchi

Yui Yamaura

Mizuki Kawahira

Kana Iwasaki

Yoriko Okamatsu

Provided is a compound having &#x3b1;4 integrin inhibitory action. The compound is a sulfonamide derivative represented by the following formula (I), or pharmaceutically acceptable salt thereof: where Rto R, e to h, D, and B represent those as described in the specification.

Substituted benzenesulfonamides as inhibitors of alpha-4 beta-7 integrin activity

A method of screening a compound having a hypoglycemic effect (hereinafter referred to as 'hypoglycemic compound'), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the &#x3b2; subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the &#x3b2; subunit of a trimeric GTP-binding protein, as the active ingredient, etc.

Remedy for diabetes

The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R' represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R&#x2033; represent a hydrogen atom.

Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof

The present invention provides a lactam compound, a sugar transport enhancement agent containing this compound as an active ingredient, an agent for the prevention and/or treatment of diabetes mellitus, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macrovascular disease, glucose tolerance anomaly, obesity and the like. In addition, the present invention also provides a preparation method for the novel lactam compound, and a preparation intermediate thereof.

Lactam compound, a method for producing the same, and a diabetic therapy by administering the same

Growing community of inventors

Kawasaki, Japan

Wataru Miyanaga